Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration

Abstract

The significant gains in BCVA at 3 months were the same or better at 12 months in all conbercept dosing groups of neovascular AMD patients. During the 12 months, repeated intravitreal injections of conbercept were well tolerated in these patients. Future clinical trials are required to confirm its long-term efficacy and safety.

Subconjunctival Bevacizumab Injection Impairs Corneal Innervations and Epithelial Wound Healing in Mice

“…4,5,9,11 The dual roles of VEGF in the vascular and nervous systems led to consideration of the potential neuronal risk of anti-VEGF therapies, which are being widely used to treat ocular diseases. [12][13][14][15] The cornea is the most densely innervated tissue in the human body and is dominantly supplied by the sensory nerve fibers derived from the neurons located in the trigeminal ganglion. In the subbasal layer, the corneal nerve fibers form a distinctive pinwheel pattern plexus and project toward the apical surface of the corneal epithelium.…”

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

“…retinal vein occlusion trial of conbercept, AURORA, demonstrated the drug to be safe and efficacious with as needed dosing (Li et al 2014a). Recent concerns have been raised regarding possible increase in geographic atrophy with anti-VEGF administration, particularly ranibizumab (Grunwald et al 2014(Grunwald et al , 2015.…”

Advances in pharmacotherapy for wet age-related macular degeneration

“…KH902 can bind and inhibit all VEGF-A isoforms, VEGF-B, VEGF-C, PlGF-1, and -2, and phosphatidylinositol-3-kinases (PI3K) [53,54]. Preclinical data suggest that KH902 has marked inhibitory effects on angiogenesis both in vitro and in vivo [53], as it significantly inhibits the growth of new vessels and promotes the regression of the established ones [55].…”